TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Number of Subjects With Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentrations Equal to or Above Cut-off Values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: flaremetry readings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: protein content of the aqueous humor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative inflammatory complications
Endpoint domain: Adverse events/effects
Primary endpoint: safety and tolerability of KW 2450
Endpoint domain: Adverse events/effects
Primary endpoint: Tregs levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Post COVID symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Haemoglobin levels at birth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Intraventricular Haemorrhage
Endpoint domain: Adverse events/effects
Primary endpoint: Midazolam concentration in serum and urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment session attendance
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Global PANSS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length of time of utilization of SNOO
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in 6 minute walk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global symptoms score (GSS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Volumetric analysis of autologous fat graft
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensivity Improvement Using the ASIA Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Functional Independence Measure Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Barthel Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Proportion of patients experiencing clinically relevant improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood sugar change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mood change
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Tissue Collection
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Smoking Status after Quit Attempt
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in mucosal integrity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Freedom from episodes of atrial fibrillation > 30 seconds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum tolerated dose or pharmacologically active dose (PAD) of INCAGN02390
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rate of patients who remain progression free
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of patients who remain progression free
Endpoint domain: Mortality/survival
Primary endpoint: Change in sitting time (objective)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in physical activity level (objective)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in sitting time (subjective)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in physical activity level (subjective)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Synaptic Density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Limited CLASI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS for Appearance
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: VAS for Pain
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Implant survival at 2 years
Endpoint domain: Mortality/survival
Primary endpoint: Visual Analogue Score (VAS)
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Absence of rebleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Health Care Quality Ranking
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: ED Visits Per Child
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Inpatient Admissions Per Child
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Hospital Days Per Child
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: lower incidence of infection
Endpoint domain: Adverse events/effects
Primary endpoint: Absolute Change From Baseline in Inflammatory Lesion Count at Week 40
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage of Participants Achieving Investigator's Global Assessments (IGA) Treatment Success at Week 40
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Incidence of sedation related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Need for airway maneuvers
Endpoint domain: Adverse events/effects
Primary endpoint: Total Medical Costs Per Member Per Month
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Total Medical Costs That Can be Impacted Per Member Per Month
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Patients' distress due to delusional thinking
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Difference in vancomycin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum Ustekinumab Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change From Baseline in LDL-C at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in flow mediated dilation of the brachial artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Immunogenicity of HPV-16/18 vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Range of Movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Concentration of fecal calprotectin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Concentration of fecal elastase-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in small bowel capsule endoscopy (SBCE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Efficacy of anti-multiresistant empirical antibiotic therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of Participants With Measles Antibody Levels ≥255 mIU/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With Mumps Antibody Levels ≥10 Mumps Antibody Units/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With Rubella Antibody Levels ≥10 IU/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With Varicella-zoster Virus (VZV) Antibody Levels ≥5 Glycoprotein Enzyme-linked Immunosorbent Assay (gpELISA) Units/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Plasma steady-state DTG PK parameters AUC(0-τ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma steady-state DTG PK parameters Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma steady-state DTG PK parameters Cmin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma steady-state DTG PK parameters Cτ
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Invisible blood loss after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Time (seconds) taken to perform time up and go test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Consumption of analgesics (oxycodone)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Expression of CD28 in CD4+ Allergen Specific T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Amount of linaclotide and its active metabolite excreted in breast milk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Present Pain Intensity Index (PPI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Active mitochondria content of alveolar macrophages
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Spielberger STAI test
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: standardized area under the curve for FEV1 (FEV1 AUC0-3)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in the volume of the ischemic lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Use of very effective contraception
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Proportion of Subjects Who Achieved ASAS20 Clinical Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Children's Cognitive Development
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Children's Health
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parental Postnatal Investment Behavior
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Educational Status
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Malaria seropositivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Comparative assessment of patient outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptomatic Respiratory Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Proportion of participants that develop Grade 3 or 4 local reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of participants that develop Grade 3 or 4 systemic reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Gastric emptying half time (GE t1/2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Minimal Effective Volume (MEV90) of Intraneural Ropivacaine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Palatability of clindamycin liquid
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Taste reactivity of clindamycin liquid
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in skin melanin density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change of office systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of LDL cholesterol control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of HbA1c control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mini Mental Test Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: patient-reported pain
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: mean non-invasive blood pressure (MAP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in Carbon Dioxide Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of long-term postoperative cognitive dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: AUC(0- ∞) of Unconjugated Rotigotine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-t of Atorvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of Atorvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCt of Fenofibric acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of Fenofibric acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SNP array and whole exome sequencing data
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Responses recorded
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of Intra-dialytic Hypotension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Decline in Systolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum concentration (Cmax observed)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration vs. time curve (AUCt)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: extent of pituitary down-regulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Total Corneal Fluorescein Staining
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ocular Discomfort
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Days of treatment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Incidence of MedStream system-related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Mayo score comparison
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Pathological evaluation comparison
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Intra-and inter-observer agreement
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of symptomatic CRB
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of COVID-19
Endpoint domain: Mortality/survival
Primary endpoint: Glucocorticoid-related adrenal insufficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Glucocorticoid-related Cushing syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Discomfort associated with peripheral IV placement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Clinical course of MNGIE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to progression to definite MS (second attack)
Endpoint domain: Mortality/survival
Primary endpoint: Patient Accrual Rate Over One Year
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: maturation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnosis of ASD at 24 months corrected age
Endpoint domain: Mortality/survival
Primary endpoint: Acceptability of the coached version of My MS Toolkit
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Feasibility of the coached version of My MS Toolkit
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Freedom from a composite of major adverse events (MAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Freedom from clinically-driven target lesion revascularization (CDTLR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Changes in overground gait speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change Eating behaviours
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Change Affective symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change From Baseline in Log10 HIV RNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Granulocytic differentiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Myeloid cell proliferation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Patient-defined treatment success
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patients' will to experience adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of virologically cured (PCR-negative status)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IOP change over 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Who Achieved ACR20
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Reach the Maximum Concentration (Tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Observed Maximum Serum Concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Epidermal Thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: NIV Tolerance Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidences of ASN-002 related Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence Rate of New Digital Ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Degree of improvement in patients with Duchenne Muscular Dystrophy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change From Baseline in Weekly Average Daily Pain Score (ADPS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Periprocedural myocardial injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Onset Time of Sciatic Nerve Block
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of symptomatic non-anastomotic biliary strictures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: First-dose blood concentrations with maximum antimicrobial activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Steady-state blood concentrations with maximum antimicrobial activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Gastrointestinal Toxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Shoulder Internal and External Rotation Range of Motion Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Posterior Shoulder Capsule Tightness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Shoulder Strength Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trunk Muscles Endurance Test - (McGill Trunk Endurance Test)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sera titer ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Skin-to-muscle and muscle-to-bone distance assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Continental genetic ancestry fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes of the PAM50 11-gene proliferation signature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite criteria of morbid/mortality
Endpoint domain: Mortality/survival
Primary endpoint: Time to first occurrence of VTE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change in Fluorothymidine F-18 mean standardized uptake value (SUV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change from baseline in Unified Parkinson's Disease Rating Scale (UPDRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: d3mft
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postprandial area under the glucose curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Plasma BNP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Plasma NT-proBNP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Plasma MR-proANP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of neuromuscular block reversal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change From Baseline in Myocardium Mass Infarct Size at Month 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Clinically Significant Post-operative Pancreatic Fistula (POPF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes